Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 6Prostatic Neoplasms 5Glioma 2Glioblastoma 2Disease 2Urinary Bladder Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1

Interventions

olaparib 4Pluvicto 4Abiraterone Acetate 4Prednisone 3Prednisolone 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2enzalutamide 2darolutamide 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1niraparib 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1cabozantinib 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × fluciclovine F-18 × 1 year × Clear all
NCT04158245 2025-09-22

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Tulane University

Phase 2 Completed
9 enrolled 14 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡